TEST CHANGE

CV2.1 Antibody, IgG~~Screen~~ by CBA-IFA with Reflex to Titer, CSF

3002257, CV2.1 CSF

Specimen Requirements:	
Patient Preparation:	
Collect:	CSF.
Specimen Preparation:	Transfer 0.5 mL CSF to an ARUP standard transport tube.~~Standard Transport Tube.~~ (Min: 0.15 mL)
Transport Temperature:	Refrigerated.
Unacceptable Conditions:	Hemolyzed, contaminated, or severely lipemic specimens.
Remarks:	
Stability:	Ambient: 48 hours; Refrigerated: 2 weeks; Frozen: 1 month
Methodology:	Semi-Quantitative Cell-Based Indirect Fluorescent Antibody
Performed:	Thu
Reported:	1-8 days
Note:	If CV2.1 Antibody IgG Screen by IFA, CSF is positive, then CV2.1 Antibody IgG Titer, CSF will be added. Additional charges apply.
CPT Codes:	86255; if reflexed, add 86256
New York DOH Approval Status:	This test is New York DOH approved.

Interpretive Data:

CV2.1 antibodies aid in discriminating between chronic paraneoplastic neurological disorder (PND) and other inflammatory disorders of the nervous system. Anti-CV2.1 is associated with small-cell lung cancer and thymoma. A negative test result does not rule out a diagnosis of autoimmune neurologic disease. Results should be interpreted in correlation with the patient's clinical history and other laboratory findings.

This indirect fluorescent antibody assay utilizes CV2.1 transfected cell lines for the detection and semiquantification of the CV2.1 IgG antibody.

Reference Interval:

Less than 1:1